124 related articles for article (PubMed ID: 17265035)
1. Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas.
Kneifel S; Bernhardt P; Uusijärvi H; Good S; Plasswilm L; Buitrago-Téllez C; Müller-Brand J; Mäcke H; Merlo A
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1388-95. PubMed ID: 17265035
[TBL] [Abstract][Full Text] [Related]
2. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.
Schumacher T; Hofer S; Eichhorn K; Wasner M; Zimmerer S; Freitag P; Probst A; Gratzl O; Reubi JC; Maecke R; Mueller-Brand J; Merlo A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):486-93. PubMed ID: 11914886
[TBL] [Abstract][Full Text] [Related]
3. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
[TBL] [Abstract][Full Text] [Related]
6. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
7. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.
Kneifel S; Cordier D; Good S; Ionescu MC; Ghaffari A; Hofer S; Kretzschmar M; Tolnay M; Apostolidis C; Waser B; Arnold M; Mueller-Brand J; Maecke HR; Reubi JC; Merlo A
Clin Cancer Res; 2006 Jun; 12(12):3843-50. PubMed ID: 16778112
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC.
Ferrari M; Cremonesi M; Bartolomei M; Bodei L; Chinol M; Fiorenza M; Tosi G; Paganelli G
J Nucl Med; 2006 Jan; 47(1):105-12. PubMed ID: 16391194
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
[TBL] [Abstract][Full Text] [Related]
10. [Volumetric changes following 125I interstitial brachytherapy of gliomas].
Julow J; Viola A; Major T; Mangel L; Bajzik G; Repa I; Sági S; Valálik I; Emri M; Trón L; Németh G
Ideggyogy Sz; 2005 Mar; 58(3-4):120-32. PubMed ID: 15887415
[TBL] [Abstract][Full Text] [Related]
11. 90Y PET-based dosimetry after selective internal radiotherapy treatments.
D'Arienzo M; Chiaramida P; Chiacchiararelli L; Coniglio A; Cianni R; Salvatori R; Ruzza A; Scopinaro F; Bagni O
Nucl Med Commun; 2012 Jun; 33(6):633-40. PubMed ID: 22407156
[TBL] [Abstract][Full Text] [Related]
12. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
[TBL] [Abstract][Full Text] [Related]
13. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
14. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
15. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.
Paganelli G; Grana C; Chinol M; Cremonesi M; De Cicco C; De Braud F; Robertson C; Zurrida S; Casadio C; Zoboli S; Siccardi AG; Veronesi U
Eur J Nucl Med; 1999 Apr; 26(4):348-57. PubMed ID: 10199940
[TBL] [Abstract][Full Text] [Related]
16. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
Paganelli G; Bartolomei M; Ferrari M; Cremonesi M; Broggi G; Maira G; Sturiale C; Grana C; Prisco G; Gatti M; Caliceti P; Chinol M
Cancer Biother Radiopharm; 2001 Jun; 16(3):227-35. PubMed ID: 11471487
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates.
Hopkins K; Chandler C; Bullimore J; Sandeman D; Coakham H; Kemshead JT
Radiother Oncol; 1995 Feb; 34(2):121-31. PubMed ID: 7597210
[TBL] [Abstract][Full Text] [Related]
18. [Chronologic dynamics of the "triple ring," caused by interstitial Iodine-125 brachytherapy with a novel method of image fusion].
Kolumbán Z; Viola A; Major T; Bajzik G; Julow J
Ideggyogy Sz; 2008 Mar; 61(3-4):106-13. PubMed ID: 18459451
[TBL] [Abstract][Full Text] [Related]
19. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry protocol for the preclinical trials in white-beam minibeam radiation therapy.
Prezado Y; Martinez-Rovira I; Thengumpallil S; Deman P
Med Phys; 2011 Sep; 38(9):5012-20. PubMed ID: 21978045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
